AC220 (Quizartinib) is an orally-available, imidazobenzothiazole-based inhibitor of Flt3, with an in vitro Kd of 2 nM. In vitro cell studies show that AC220 has a IC50 of 0.5 nM for MV-411 cells. [1] In a variety of leukemic cell lines, AC220 inhibited Flt3 phosphorylation of MV4-11, MOLM-14, SEM-K2, and RS4-11 at IC50s of 1, 2, 4, and 4 nM, respectively. Furthermore, inhibition of cell proliferation on these same lines were measured as 0.3, 0.1, 0.4, and >10000 nM, respectively. [2]In a KinomeScan panel of 402 kinases, AC220 has a high degree of specificity toward Flt3 with only mild inhibition of closely related RTKs such as KIT, PDGFR, RET, VEGFR2. [3]Ina Flt3-ITD acute myeloid leukemia mouse model, AC220 was shown to extend significantly the survival at 1 mg/kg QD dosing, and eradicates tumors in a Flt3-dependent mouse xenograft model at 10 mg/kg. [3]

Technical information:

Shipping Condition: The product is shipped in a glass vial at ambient temperature.Storage condition: For longer shelf life, store solid powder at 4^oC desiccated, or store DMSO solution at -20^oC.

Reference:

Other Information:

Product Specification (pdf) MSDS (pdf) Certificate of Analysis is available upon request.

Cellagen利用广泛的研究以及我们在干细胞生物学，药物化学和产品开发方面的专业知识，Cellagen长期以来一直为专业OEM产品提供世界领先的公司，为一线干细胞研究奠定了基础。

现在，Cellagen扩展了其最佳产品系列，并直接向研究界提供。Cellagen与世界领先的科学家有着密切的联系，并且始终认识到高标准科学研究的未满足需求。